RWA Moderna’s stock surged 131% after a Phase 3 trial showed its cancer vaccine outperformed standard care, delivering a major win for the biotech. Short sellers faced $4.8 billion in losses as the news triggered a massive rally. This development highlights the potential of mRNA technology in oncology beyond infectious diseases.